Browse All

Current Filters

CLEAR FILTER x

TITLE

Treatment Outcomes in People with Migraine Receiving Rimegepant or Triptans: A Descriptive Analysis from a Real-World Survey

Author:Abraham, Lucy   Brown, Joshua   Hygge Blakeman, Karin   Feng, Dai   Jackson, James   Whitton, William   Barlow, Sophie   Hancock, Lucy   

Session Name:P1: Headache: Population Health and Outcomes Research  

Topic:Headache  

Program Number:P1.008  

Author Institution:Pfizer R&D UK Ltd, Tadworth, United Kingdom  Pfizer, Inc., New York, NY  Pfizer AB, Stockholm, Sweden  Adelphi Real World, Manchester, United Kingdom  Adelphi Real World, Macclesfield, United Kingdom  

Time to First and Sustained Improvement in Weekly Migraine Days Among Patients Receiving Preventive Treatment With Rimegepant 75 mg

Author:Tepper, Stewart   Abraham, Lucy   Bushmakin, Andrew   Cappelleri, Joseph   Fullerton, Terence   Yang, Jiyue   Lipton, Richard   

Session Name:P9: Headache: Advances in CGRP Inhibitors and Migraine 2  

Topic:Headache  

Program Number:P9.005  

Author Institution:New England Institute for Neurology and Headache, Stamford, CT  Pfizer R&D UK Ltd, Tadworth, United Kingdom  Pfizer Inc, Groton, CT  Pfizer Inc, New York, NY  Montefiore Headache Center and the Albert Einstein College of Medicine, New York, NY